Dr. Jordan answers the question: 'How can I be estrogen receptor-positive?' — -- Question: How can my breast cancer be estrogen receptor-positive when I am postmenopausal and my body is losing ...

Roche RHHBY announced that the FDA has accepted its new drug application (NDA) for giredestrant, an investigational oral therapy, in combination with everolimus, for the treatment of adult patients ...

The FDA application is supported by data from the Phase 3 evERA Breast Cancer study. The trial results showed that the combination of giredestrant and Afinitor reduced the risk of disease progression ...

The clinically meaningful benefit seen with giredestrant could enable an important new treatment option to help delay disease progression or death in people with advanced, ER-positive breast cancer,” ...

Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...

The modulation of colorectal cancer (CRC) by oestrogen receptors has emerged as a field of great promise, drawing attention to the differential roles of receptor subtypes in tumour initiation, ...

Estrogen, the major female ovarian hormone, can trigger nerve impulses within milliseconds to regulate a variety of physiological processes. At Baylor College of Medicine, Louisiana State University ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

Researchers found that mice lacking membrane ERα signaling in osteoblast lineage cells had significantly lower cortical bone mass, highlighting the pathway’s critical role in maintaining the strength ...